Journal: Oncology letters

Article Title: Identification of AKT1 /β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.

doi: 10.3892/ol.2021.12470

Figure Lengend Snippet: Figure 1. Effect of AKT1/CTNNB1 mutations on cetuximab resistance. Effect of (A) AKT1 E17K, E49K and L52R and, (B) CTNNB1 T41A, S45F and S33P on cetuximab resistance. *P<0.02 vs. respective WT. WT, wild‑type. CTNNB1, β-catenin.

Article Snippet: Human AKT1 and CTNNB1 pCMV6‐entry vectors with C‐terminal Myc‐DDK tag were purchased from OriGene Technologies Inc. (cat. nos.

Techniques:

Journal: Oncology letters

Article Title: Identification of AKT1 /β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.

doi: 10.3892/ol.2021.12470

Figure Lengend Snippet: Figure 2. Effect of AKT1/CTNNB1 mutations on oxaliplatin resistance. Effect of (A) AKT1 E17K, E49K and L52R and (B) CTNNB1 T41A, S45F and S33P on oxaliplatin resistance. *P<0.02 vs. respective WT. CTNNB1, β-catenin; WT, wild‑type.

Article Snippet: Human AKT1 and CTNNB1 pCMV6‐entry vectors with C‐terminal Myc‐DDK tag were purchased from OriGene Technologies Inc. (cat. nos.

Techniques:

Journal: Oncology letters

Article Title: Identification of AKT1 /β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.

doi: 10.3892/ol.2021.12470

Figure Lengend Snippet: Figure 3. Effect of AKT1/CTNNB1 mutations on irinotecan resistance. Effect of (A) AKT1 E17K, E49K and L52R (B) CTNNB1 T41A, S45F and S33P on irinotecan resistance. *P<0.02 vs. respective WT. CTNNB1, β-catenin; WT, wild‑type.

Article Snippet: Human AKT1 and CTNNB1 pCMV6‐entry vectors with C‐terminal Myc‐DDK tag were purchased from OriGene Technologies Inc. (cat. nos.

Techniques:

Journal: Oncology letters

Article Title: Identification of AKT1 /β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.

doi: 10.3892/ol.2021.12470

Figure Lengend Snippet: Figure 4. Effect of AKT1/CTNNB1 mutations on SN‑38 resistance. Effect of (A) AKT1 E17K, E49K and L52R and (B) CTNNB1 T41A, S45F and S33P on SN‑38 resistance. *P<0.02 vs. respective WT. CTNNB1, β-catenin; WT, wild‑type.

Article Snippet: Human AKT1 and CTNNB1 pCMV6‐entry vectors with C‐terminal Myc‐DDK tag were purchased from OriGene Technologies Inc. (cat. nos.

Techniques:

Journal: Oncology letters

Article Title: Identification of AKT1 /β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.

doi: 10.3892/ol.2021.12470

Figure Lengend Snippet: Figure 5. Effect of AKT1/CTNNB1 mutations on 5‑FU resistance. Effect of (A) AKT1 E17K, E49K and L52R (B) CTNNB1 T41A, S45F and S33P on 5‑FU resistance. *P<0.02 vs. respective WT. CTNNB1, β-catenin; WT, wild‑type; 5‑FU, 5‑fluorouracil.

Article Snippet: Human AKT1 and CTNNB1 pCMV6‐entry vectors with C‐terminal Myc‐DDK tag were purchased from OriGene Technologies Inc. (cat. nos.

Techniques:

Journal: Oncology letters

Article Title: Identification of AKT1 /β-catenin mutations conferring cetuximab and chemotherapeutic drug resistance in colorectal cancer treatment.

doi: 10.3892/ol.2021.12470

Figure Lengend Snippet: Figure 6. Western blot analysis of AKT1 variants. (A) Immunoreactive AKT1 and GAPDH protein bands and (B) AKT1 WT, E17K, E49K and L52R protein levels. GAPDH was used as the internal control for gene expression. Anti‑DDK monoclonal antibody was used for AKT1 detection. n=3. *P<0.02 vs. respective WT. EV, empty vector; WT, wild‑type.

Article Snippet: Human AKT1 and CTNNB1 pCMV6‐entry vectors with C‐terminal Myc‐DDK tag were purchased from OriGene Technologies Inc. (cat. nos.

Techniques: Western Blot, Control, Gene Expression, Plasmid Preparation